Incyte is gearing up for a Jakafi label expansion, announcing Thursday plans to submit the bone marrow drug to treat graft-versus-host disease in the third quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,